Department of General Surgery, Colorectal Division, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, 400000, People's Republic of China.
Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100000, People's Republic of China.
Int J Surg. 2018 Jul;55:128-138. doi: 10.1016/j.ijsu.2018.05.030. Epub 2018 May 26.
The lymphocyte to monocyte ratio, an inflammation-based score, has been used to predict the biological behavior of malignant tumors. However, the relationship between the lymphocyte to monocyte ratio and clinical outcomes in patients with colorectal cancer remains controversial. We conducted a meta-analysis to identify the association between the lymphocyte to monocyte ratio and the prognosis of patients with colorectal cancer.
Data were retrieved from PubMed, Embase, and Web of science, the hazard ratio and odds ratios with 95% confidence intervals were used to assess the prognostic value of the lymphocyte to monocyte ratio. Outcomes of interest included prognosis, such as overall survival, disease-free survival, and cancer-specific survival in patients with colorectal cancer.
fifteen retrospective, observational, cohort studies involving 11,783 patients were identified. A high lymphocyte to monocyte ratio (LMR) was a significant predictor of better overall survival (hazard ratio = 0.57, 95% confidence interval: 0.52-0.62, P < 0.001), disease-free survival (hazard ratio = 0.77, 95% confidence interval: 0.70-0.84, P < 0.001), and cancer-specific survival (hazard ratio = 0.55, 95% confidence interval: 0.32-0.95, P = 0.031). Increased LMR is also significantly associated with the tumor invasion depth (OR: 0.77, 95% CI: 0.61-0.97) and tumor size (OR: 0.74, 95% CI: 0.61-0.89).
Our study indicated that a high lymphocyte to monocyte ratio might be a useful marker for colorectal cancer prognosis. As most of these findings were from retrospective studies, further studies are needed to verify the significance of the lymphocyte to monocyte ratio in clinical practice.
淋巴细胞与单核细胞比值（LMR）是一种基于炎症的评分，已被用于预测恶性肿瘤的生物学行为。然而，LMR 与结直肠癌患者临床结局之间的关系仍存在争议。我们进行了一项荟萃分析，以确定 LMR 与结直肠癌患者预后之间的关系。
从 PubMed、Embase 和 Web of Science 中检索数据，使用风险比和比值比及其 95%置信区间来评估 LMR 的预后价值。感兴趣的结局包括结直肠癌患者的预后，如总生存、无病生存和癌症特异性生存。
确定了 15 项回顾性、观察性、队列研究，涉及 11783 名患者。高 LMR 是总生存（风险比=0.57，95%置信区间：0.52-0.62，P<0.001）、无病生存（风险比=0.77，95%置信区间：0.70-0.84，P<0.001）和癌症特异性生存（风险比=0.55，95%置信区间：0.32-0.95，P=0.031）的显著预测因子。LMR 升高还与肿瘤浸润深度（OR：0.77，95%CI：0.61-0.97）和肿瘤大小（OR：0.74，95%CI：0.61-0.89）显著相关。
本研究表明，高 LMR 可能是结直肠癌预后的有用标志物。由于这些发现大多来自回顾性研究，因此需要进一步的研究来验证 LMR 在临床实践中的意义。
